NICE now recommends Ocrevus to treat relapsing remitting MS under specific conditions.- Roche.
The National Institute for Health and Care Excellence (NICE) has recommended that Ocrevus (ocrelizumab) from Roche can be prescribed for relapsing remitting multiple sclerosis if a patient is experiencing relapses or has MRI evidence of new areas of MS activity, and alemtuzumab is contraindicated or otherwise unsuitable. This decision reverses NICE’s earlier rejection that it did not intend to recommend ocrelizumab for relapsing MS. Roche has agreed to a confidential discount.
Comment: NICE also referred to patients’ need for less frequent dosing or monitoring as a factor that influenced its decision. After the first dose, given in two separate infusions 2 weeks apart, Ocrevus is administered once every 6 months with fewer adverse effects compared with some other treatments.
160 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.